Ashraf Abu Jama

Beersheba, D 84105, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Impact of Angiotensin-Converting Enzyme Inhibitors (ACEIs) on the Efficacy of Immunotherapy in Metastatic NSCLC.

Impact of Angiotensin-Converting Enzyme Inhibitors (ACEIs) on the Efficacy of Immunotherapy in Metastatic NSCLC.

Journal: Medical sciences (Basel, Switzerland)

Published: June 26, 2026

Impact of PD-L1 Status on the Development of Cutaneous Immune-Related Adverse Events in Non-Small-Cell Lung Cancer Patients Receiving Immunotherapy.

Impact of PD-L1 Status on the Development of Cutaneous Immune-Related Adverse Events in Non-Small-Cell Lung Cancer Patients Receiving Immunotherapy.

Journal: Life (Basel, Switzerland)

Published: March 02, 2026

Evaluating the Therapeutic Impact of Immune Checkpoint Inhibitors in the Management of Brain Metastases from Non-Small Cell Lung Cancer.

Evaluating the Therapeutic Impact of Immune Checkpoint Inhibitors in the Management of Brain Metastases from Non-Small Cell Lung Cancer.

Journal: Biomedicines

Published: February 05, 2026

Impact of Statin Use on Immunotherapy Outcomes and Efficacy in Non-Small Cell Lung Cancer Patients.

Impact of Statin Use on Immunotherapy Outcomes and Efficacy in Non-Small Cell Lung Cancer Patients.

Journal: International journal of molecular sciences

Published: January 07, 2026

Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases.

Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases.

Journal: Medical sciences (Basel, Switzerland)

Published: August 17, 2025

Analysis of Metastases and Second Primary Malignancy Development in Patients with Invasive Transitional Cell Carcinoma of the Bladder.

Analysis of Metastases and Second Primary Malignancy Development in Patients with Invasive Transitional Cell Carcinoma of the Bladder.

Journal: Cancers

Published: July 16, 2025

Exploring the Impact of TP53 Mutation and Wild-Type Status on the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer.

Exploring the Impact of TP53 Mutation and Wild-Type Status on the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer.

Journal: International journal of molecular sciences

Published: June 07, 2025

Correlation Between Body Mass Index and Immunotherapy Response in Advanced NSCLC.

Correlation Between Body Mass Index and Immunotherapy Response in Advanced NSCLC.

Journal: Cancers

Published: February 27, 2025

Colorectal Cancer in Elderly Patients: Insights into Presentations, Prognosis, and Patient Outcomes.

Colorectal Cancer in Elderly Patients: Insights into Presentations, Prognosis, and Patient Outcomes.

Journal: Medicina (Kaunas, Lithuania)

Published: October 03, 2024

Adverse Events in Osimertinib Treatment for EGFR-Mutated Non-Small-Cell Lung Cancer: Unveiling Rare Life-Threatening Myelosuppression.

Adverse Events in Osimertinib Treatment for EGFR-Mutated Non-Small-Cell Lung Cancer: Unveiling Rare Life-Threatening Myelosuppression.

Journal: Medicina (Kaunas, Lithuania)

Published: July 11, 2024

Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1 and TMB Status.

Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1 and TMB Status.

Journal: Cancers

Published: April 08, 2024

Perimyocarditis Associated with Immune Checkpoint Inhibitors: A Case Report and Review of the Literature.

Perimyocarditis Associated with Immune Checkpoint Inhibitors: A Case Report and Review of the Literature.

Journal: Medicina (Kaunas, Lithuania)

Published: December 21, 2023

Showing 1-12 of 17

Last Updated: 09/26/2026